Image 1 of 2
Image 2 of 2
RETATRUTIDE 10MG
Each vial contains 10mg of highly pure Retatrutide.
Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously. Semaglutide covers one of those. Tirzepatide covers two. Retatrutide is the only compound that covers all three — and that third pathway (glucagon) adds something the other two can’t: direct effects on energy expenditure and hepatic lipid metabolism. It’s not just additive. The glucagon receptor brings an entirely new dimension.
Published Phase 2 clinical trial data showed dose-dependent results across multiple cohorts, making it the most extensively documented tri-agonist in existence. No other commercially available peptide hits all three receptors. If the goal is to study how GIP, GLP-1, and glucagon signaling interact, there’s no alternative — retatrutide is currently the only tool that does it.
Each vial contains 10mg of highly pure Retatrutide.
Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously. Semaglutide covers one of those. Tirzepatide covers two. Retatrutide is the only compound that covers all three — and that third pathway (glucagon) adds something the other two can’t: direct effects on energy expenditure and hepatic lipid metabolism. It’s not just additive. The glucagon receptor brings an entirely new dimension.
Published Phase 2 clinical trial data showed dose-dependent results across multiple cohorts, making it the most extensively documented tri-agonist in existence. No other commercially available peptide hits all three receptors. If the goal is to study how GIP, GLP-1, and glucagon signaling interact, there’s no alternative — retatrutide is currently the only tool that does it.